These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21170569)

  • 1. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?
    Omuro A; Taillandier L; Chinot O; Sierra Del Rio M; Carnin C; Barrie M; Soussain C; Tanguy ML; Choquet S; Leblond V; Hoang-Xuan K;
    J Neurooncol; 2011 Aug; 104(1):323-30. PubMed ID: 21170569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
    Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
    J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience.
    Chanswangphuwana C; Rojnuckarin P; Cherdchoo N; Raiyawa T; Uaprasert N
    Hematology; 2018 Aug; 23(7):385-390. PubMed ID: 29256330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
    Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Pfreundschuh M; Cabras G; Angrilli F; Ponzoni M; Deckert M; Politi LS; Finke J; Reni M; Cavalli F; Zucca E; Illerhaus G;
    Lancet Haematol; 2017 Nov; 4(11):e510-e523. PubMed ID: 29054815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and opportunities in primary CNS lymphoma: A systematic review.
    Kerbauy MN; Moraes FY; Lok BH; Ma J; Kerbauy LN; Spratt DE; Santos FP; Perini GF; Berlin A; Chung C; Hamerschlak N; Yahalom J
    Radiother Oncol; 2017 Mar; 122(3):352-361. PubMed ID: 28104300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
    Morris PG; Correa DD; Yahalom J; Raizer JJ; Schiff D; Grant B; Grimm S; Lai RK; Reiner AS; Panageas K; Karimi S; Curry R; Shah G; Abrey LE; DeAngelis LM; Omuro A
    J Clin Oncol; 2013 Nov; 31(31):3971-9. PubMed ID: 24101038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.
    Correa DD; Braun E; Kryza-Lacombe M; Ho KW; Reiner AS; Panageas KS; Yahalom J; Sauter CS; Abrey LE; DeAngelis LM; Omuro A
    J Neurooncol; 2019 Sep; 144(3):553-562. PubMed ID: 31377920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine.
    Hattori K; Sakata-Yanagimoto M; Okoshi Y; Kato T; Kurita N; Yokoyama Y; Obara N; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Hasegawa Y; Chiba S
    J Clin Exp Hematop; 2017 Oct; 57(2):41-46. PubMed ID: 28781291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
    Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
    Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
    Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G
    Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study.
    Montemurro M; Kiefer T; Schüler F; Al-Ali HK; Wolf HH; Herbst R; Haas A; Helke K; Theilig A; Lotze C; Hirt C; Niederwieser D; Schwenke M; Krüger WH; Dölken G
    Ann Oncol; 2007 Apr; 18(4):665-71. PubMed ID: 17185743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
    Shah GD; Yahalom J; Correa DD; Lai RK; Raizer JJ; Schiff D; LaRocca R; Grant B; DeAngelis LM; Abrey LE
    J Clin Oncol; 2007 Oct; 25(30):4730-5. PubMed ID: 17947720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.
    Houillier C; Taillandier L; Dureau S; Lamy T; Laadhari M; Chinot O; Moluçon-Chabrot C; Soubeyran P; Gressin R; Choquet S; Damaj G; Thyss A; Abraham J; Delwail V; Gyan E; Sanhes L; Cornillon J; Garidi R; Delmer A; Tanguy ML; Al Jijakli A; Morel P; Bourquard P; Moles MP; Chauchet A; Gastinne T; Constans JM; Langer A; Martin A; Moisson P; Lacomblez L; Martin-Duverneuil N; Delgadillo D; Turbiez I; Feuvret L; Cassoux N; Touitou V; Ricard D; Hoang-Xuan K; Soussain C;
    J Clin Oncol; 2019 Apr; 37(10):823-833. PubMed ID: 30785830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.
    Karmali R; Nabhan C; Petrich AM; Raizer J; Peace D; Lukas R; Gordon LI; Basu S; Chukkapalli V; Venugopal P
    Br J Haematol; 2017 Apr; 177(1):72-79. PubMed ID: 28211579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.
    Doolittle ND; Korfel A; Lubow MA; Schorb E; Schlegel U; Rogowski S; Fu R; Dósa E; Illerhaus G; Kraemer DF; Muldoon LL; Calabrese P; Hedrick N; Tyson RM; Jahnke K; Maron LM; Butler RW; Neuwelt EA
    Neurology; 2013 Jul; 81(1):84-92. PubMed ID: 23685932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom.
    Kassam S; Chernucha E; O'Neill A; Hemmaway C; Cummins T; Montoto S; Lennard A; Adams G; Linton K; McKay P; Davies D; Rowntree C; Easdale S; Eyre TA; Marcus R; Cwynarski K; Fox CP
    Bone Marrow Transplant; 2017 Sep; 52(9):1268-1272. PubMed ID: 28581466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma.
    Hottinger AF; DeAngelis LM; Yahalom J; Abrey LE
    Neurology; 2007 Sep; 69(11):1178-82. PubMed ID: 17846417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival following radiotherapy and cytarabine chemotherapy for sporadic primary central nervous system lymphoma.
    Pöttgen C; Stuschke M; Stüben G; Schmitz A; Schwechheimer K; Wacker HH; Rauhut F; Kleuker S; Wilhelm H; Grehl S; Fehlings T
    Strahlenther Onkol; 2003 Sep; 179(9):626-32. PubMed ID: 14628129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma.
    Gerard LM; Imrie KR; Mangel J; Buckstein R; Doherty M; Mackenzie R; Cheung MC
    Leuk Lymphoma; 2011 Oct; 52(10):1882-90. PubMed ID: 21663504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.